Risk of Chronic Kidney Disease in Hospitalized Patients with Hidradenitis Suppurativa.
Acne inversa
Comorbidity
Hidradenitis suppurativa
Kidney disease
Renal disease
Journal
Dermatology (Basel, Switzerland)
ISSN: 1421-9832
Titre abrégé: Dermatology
Pays: Switzerland
ID NLM: 9203244
Informations de publication
Date de publication:
2023
2023
Historique:
received:
22
07
2021
accepted:
23
06
2023
medline:
7
12
2023
pubmed:
25
7
2023
entrez:
24
7
2023
Statut:
ppublish
Résumé
Hidradenitis suppurativa (HS) is associated with several comorbidities such as diabetes mellitus and cardiovascular diseases. These comorbidities are also risk factors for chronic kidney disease (CKD), yet little is known about the risk of CKD in HS patients. The objective was to study the prevalence of CKD in HS patients. Cross-sectional population-based study using the United States National Inpatient Sample database between January 1, 2002 and December 31, 2012 was performed. We identified 23,767 hospital admissions for HS patients and 95,068 admissions for age- and gender-matched controls. The prevalence of CKD in HS patients was 6.3% (1,497/23,767) compared to non-HS controls which was 4.3% (4,052/95,068). The association of CKD was strongest in HS patients, who were ≥60 years old, 16.9% (475/2,811), male 7.3% (695/9,556), obese 7.8% (407/5,209), diabetic 12.5% (890/7,105), hyperlipidemic 13.3% (416/3,126), and had cardiovascular diseases 12.5% (631/5,045). The crude odds ratio of CKD in HS patients was 1.5 (95% CI: 1.420-1.605) compared to non-HS patients. The association remained significant after adjusting for important covariates with adjusted odds ratio of CKD in HS patients of 1.1 (95% CI: 1.014-1.176) compared to non-HS patients. Our findings show that there is a possible association of HS with CKD. Any signs of CKD should be assessed by a nephrologist as early diagnosis can hopefully prevent further progression.
Sections du résumé
BACKGROUND
BACKGROUND
Hidradenitis suppurativa (HS) is associated with several comorbidities such as diabetes mellitus and cardiovascular diseases. These comorbidities are also risk factors for chronic kidney disease (CKD), yet little is known about the risk of CKD in HS patients.
OBJECTIVES
OBJECTIVE
The objective was to study the prevalence of CKD in HS patients.
METHODS
METHODS
Cross-sectional population-based study using the United States National Inpatient Sample database between January 1, 2002 and December 31, 2012 was performed.
RESULTS
RESULTS
We identified 23,767 hospital admissions for HS patients and 95,068 admissions for age- and gender-matched controls. The prevalence of CKD in HS patients was 6.3% (1,497/23,767) compared to non-HS controls which was 4.3% (4,052/95,068). The association of CKD was strongest in HS patients, who were ≥60 years old, 16.9% (475/2,811), male 7.3% (695/9,556), obese 7.8% (407/5,209), diabetic 12.5% (890/7,105), hyperlipidemic 13.3% (416/3,126), and had cardiovascular diseases 12.5% (631/5,045). The crude odds ratio of CKD in HS patients was 1.5 (95% CI: 1.420-1.605) compared to non-HS patients. The association remained significant after adjusting for important covariates with adjusted odds ratio of CKD in HS patients of 1.1 (95% CI: 1.014-1.176) compared to non-HS patients.
CONCLUSIONS
CONCLUSIONS
Our findings show that there is a possible association of HS with CKD. Any signs of CKD should be assessed by a nephrologist as early diagnosis can hopefully prevent further progression.
Identifiants
pubmed: 37487485
pii: 000531960
doi: 10.1159/000531960
pmc: PMC10711764
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
912-918Informations de copyright
The Author(s). Published by S. Karger AG, Basel.
Références
Int Urol Nephrol. 2018 Jul;50(7):1277-1283
pubmed: 29644523
Br J Dermatol. 2015 Jul;173(1):146-54
pubmed: 25511692
JAMA Dermatol. 2019 Jul 1;155(7):797-802
pubmed: 30994865
JAMA Dermatol. 2017 Sep 1;153(9):897-905
pubmed: 28538949
Br J Dermatol. 2017 Apr;176(4):993-1000
pubmed: 27564400
Br J Dermatol. 2021 Oct;185(4):772-780
pubmed: 33730366
Dermatol Ther (Heidelb). 2018 Dec;8(4):557-569
pubmed: 30306395
Vestn Khir Im I I Grek. 1980 Jan;124(1):78-82
pubmed: 7376347
J Invest Dermatol. 2017 Nov;137(11):2389-2395
pubmed: 28652108
J Eur Acad Dermatol Venereol. 2018 Jan;32(1):129-144
pubmed: 28796920
Clin Exp Dermatol. 2019 Jun;44(4):e126-e132
pubmed: 30730068
Clin Exp Dermatol. 2016 Apr;41(3):287-9
pubmed: 26206410
Kidney Int Suppl (2011). 2013 Dec;3(4):368-371
pubmed: 25019021
Circulation. 2002 Mar 5;105(9):1135-43
pubmed: 11877368
J Am Acad Dermatol. 2022 May;86(5):1092-1101
pubmed: 33493574
Acta Derm Venereol. 2016 Jan;96(1):68-71
pubmed: 25710874
Kidney Int. 2021 Jan;99(1):34-47
pubmed: 33127436
Nephrol Dial Transplant. 2017 Mar 1;32(3):475-487
pubmed: 28339863
Dermatol Online J. 2012 Jan 15;18(1):2
pubmed: 22301039
Br J Dermatol. 2019 May;180(5):1009-1017
pubmed: 30552762
Dermatology. 2019;235(4):308-314
pubmed: 31121589
J Eur Acad Dermatol Venereol. 2015 Apr;29(4):619-44
pubmed: 25640693
J Am Acad Dermatol. 2019 Sep;81(3):702-708
pubmed: 31095972
Nephrol Dial Transplant. 2003 Jan;18(1):192-4
pubmed: 12480982
Transplantation. 2005 Feb 27;79(4):476-82
pubmed: 15729175
Transplantation. 2006 Sep 27;82(6):849
pubmed: 17006336
Br J Dermatol. 2011 Jun;164(6):1292-8
pubmed: 21332464
JAMA Dermatol. 2016 Apr;152(4):429-34
pubmed: 26885728
Rev Endocr Metab Disord. 2016 Sep;17(3):343-351
pubmed: 26831295
J Am Acad Dermatol. 2019 Jul;81(1):76-90
pubmed: 30872156
Dermatology. 2017;233(1):53-57
pubmed: 28448975
J Am Acad Dermatol. 2020 May;82(5):1045-1058
pubmed: 31604104
Medicine (Baltimore). 1991 Jul;70(4):246-56
pubmed: 2067409
JAMA Dermatol. 2020 Jul 1;156(7):780-786
pubmed: 32432647
Front Immunol. 2018 Dec 14;9:2965
pubmed: 30619323
Kidney Int. 2010 Jun;77(12):1070-5
pubmed: 20375986
F1000Res. 2018 Dec 13;7:1930
pubmed: 30828428
J Am Acad Dermatol. 2017 Apr;76(4):670-675
pubmed: 28041632
J Dermatolog Treat. 2018 Aug;29(5):441-449
pubmed: 29098911
Cytokine. 2018 Mar;103:20-24
pubmed: 29289722